NASDAQ:PMN Promis Neurosciences (PMN) Stock Price, News & Analysis $10.53 +0.28 (+2.73%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$10.67 +0.14 (+1.33%) As of 06/26/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Promis Neurosciences Stock (NASDAQ:PMN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Promis Neurosciences alerts:Sign Up Key Stats Today's Range$10.38▼$10.6650-Day Range$9.13▼$11.8452-Week Range$6.27▼$39.75Volume4,558 shsAverage Volume18,409 shsMarket Capitalization$94.45 millionP/E RatioN/ADividend YieldN/APrice Target$26.50Consensus RatingModerate Buy Company Overview Promis Neurosciences, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis. Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation. The company’s pipeline reflects a commitment to addressing unmet needs in neurology by optimizing compound profiles for safety, selectivity and central nervous system penetration. Promis Neurosciences collaborates with academic institutions and industry partners to accelerate its research and development efforts. These strategic alliances support biomarker identification, translational studies and clinical trial design, aiming to streamline candidate advancement and enrich patient selection strategies. The company is headquartered in the United States and its common stock trades on the Nasdaq stock exchange under the symbol PMN.AI Generated. May Contain Errors. Read More Promis Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScorePMN MarketRank™: Promis Neurosciences scored higher than 71% of companies evaluated by MarketBeat, and ranked 223rd out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingPromis Neurosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPromis Neurosciences has a consensus price target of $26.50, representing about 151.7% upside from its current price of $10.53.Amount of Analyst CoveragePromis Neurosciences has only been the subject of 4 research reports in the past 90 days.Read more about Promis Neurosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Promis Neurosciences are expected to grow in the coming year, from ($4.57) to ($3.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Promis Neurosciences is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Promis Neurosciences is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Promis Neurosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.27% of the float of Promis Neurosciences has been sold short.Short Interest Ratio / Days to CoverPromis Neurosciences has a short interest ratio ("days to cover") of 10.26, which indicates bearish sentiment.Change versus previous monthShort interest in Promis Neurosciences has recently increased by 6.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPromis Neurosciences does not currently pay a dividend.Dividend GrowthPromis Neurosciences does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.94 News SentimentPromis Neurosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Promis Neurosciences this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Promis Neurosciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.5 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $45,320.00 in company stock, which represents 0.0480% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Promis Neurosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $45,320.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders1.50% of the stock of Promis Neurosciences is held by insiders.Percentage Held by Institutions50.13% of the stock of Promis Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Promis Neurosciences' insider trading history. Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Promis Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMN Stock News HeadlinesWall Street Zen Upgrades Promis Neurosciences (NASDAQ:PMN) to "Sell"June 20, 2026 | americanbankingnews.comPromis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 18, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.June 28 at 1:00 AM | Chaikin Analytics (Ad)ProMIS Neurosciences to Participate in Upcoming Conferences in JuneMay 28, 2026 | globenewswire.comProMIS Neurosciences (PMN) Receives a Buy from GuggenheimMay 20, 2026 | theglobeandmail.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsMay 12, 2026 | finanznachrichten.deProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsMay 12, 2026 | globenewswire.comProMIS Neurosciences (PMN) price target decreased by 57.76% to 35.06March 28, 2026 | msn.comSee More Headlines PMN Stock Analysis - Frequently Asked Questions How have PMN shares performed this year? Promis Neurosciences' stock was trading at $6.8250 on January 1st, 2026. Since then, PMN shares have increased by 54.3% and is now trading at $10.53. How were Promis Neurosciences' earnings last quarter? Promis Neurosciences (NASDAQ:PMN) issued its quarterly earnings data on Tuesday, May, 12th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.06) by $0.20. When did Promis Neurosciences' stock split? Promis Neurosciences's stock reverse split before market open on Friday, November 28th 2025.A 1-25 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Promis Neurosciences' major shareholders? Top institutional investors of Promis Neurosciences include Janus Henderson Group PLC (14.41%), Ally Bridge Group NY LLC (4.62%), Yu Fan (3.68%) and ADAR1 Capital Management LLC (1.06%). Insiders that own company stock include Abg Management Ltd, Eugene Williams, Madge K Shafmaster, Patrick D Kirwin, Johanne Kaplan, Max A Milbury and Neil Cashman. View institutional ownership trends. How do I buy shares of Promis Neurosciences? Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Promis Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Promis Neurosciences investors own include PayPal (PYPL), Recursion Pharmaceuticals (RXRX), Pacific Biosciences of California (PACB), Editas Medicine (EDIT), Trimble (TRMB). Company Calendar Last Earnings5/12/2026Today6/28/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 PMN's financial health is in the Yellow zone, according to TradeSmith. PMN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMN CIK1374339 Webwww.promisneurosciences.com Phone(416) 847-6898FaxN/AEmployees5Year Founded2001Price Target and Rating Average Price Target for Promis Neurosciences$26.50 High Price Target$35.00 Low Price Target$18.00 Potential Upside/Downside+151.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($14.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-237.99% Return on Assets-151.04% Debt Debt-to-Equity RatioN/A Current Ratio9.92 Quick Ratio9.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-18.16Miscellaneous Outstanding Shares8,970,000Free Float8,833,000Market Cap$94.45 million OptionableNot Optionable Beta-0.19 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:PMN) was last updated on 6/28/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, a 20-something broker named Irving Weiss shorted the market before Black Monday and made a fortune. H...Weiss Ratings | SponsoredGold to $4,900—Here’s the Real PlayGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
